Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Stanford Health Care

Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology.

Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network Hoppe, R. T., Advani, R. H., Ai, W. Z., Ambinder, R. F., Aoun, P., Bello, C. M., Benitez, C. M., Bernat, K., Bierman, P. J., Blum, K. A., Chen, R., Dabaja, B., Forero, A., Gordon, L. I., Hernandez-Ilizaliturri, F. J., Hochberg, E. P., Huang, J., Johnston, P. B., Kaminski, M. S., Kenkre, V. P., Khan, N., Maloney, D. G., Mauch, P. M., Metzger, M., Moore, J. O., Morgan, D., Moskowitz, C. H., Mulroney, C., Poppe, M., Rabinovitch, R., Seropian, S., Smith, M., Winter, J. N., Yahalom, J., Burns, J., Ogba, N., Sundar, H. 2017; 15 (5): 608-638

Abstract

This portion of the NCCN Guidelines for Hodgkin lymphoma (HL) focuses on the management of classical HL. Current management of classical HL involves initial treatment with chemotherapy or combined modality therapy followed by restaging with PET/CT to assess treatment response using the Deauville criteria (5-point scale). The introduction of less toxic and more effective regimens has significantly advanced HL cure rates. However, long-term follow-up after completion of treatment is essential to determine potential long-term effects.

View details for PubMedID 28476741